UKHSA reaches vaccine deal with CSL Seqirus
Agreement will provide timely boost to pandemic preparedness against influenza
Read Moreby John Pinching | Sep 26, 2023 | News | 0
Agreement will provide timely boost to pandemic preparedness against influenza
Read Moreby John Pinching | Jul 7, 2023 | News | 0
Second dose of treatment generates response among young people during Oxford University trial
Read Moreby John Pinching | Jun 27, 2023 | News | 0
The company is seeking to address the worldwide impact of group B streptococcus in older adults
Read Moreby John Pinching | Jun 22, 2023 | News | 0
Poolbeg’s platform will possess the capability to generate vaccines for a wide range of diseases
Read Moreby John Pinching | Jun 13, 2023 | News | 0
VLA1553 had a high seroresponse rate among participants 28 days after receiving a single administration
Read Moreby John Pinching | Jun 6, 2023 | News | 0
Rocketvax and Basel University therapy uses a modified coronavirus that activates an immune response
Read Moreby John Pinching | May 9, 2023 | News | 0
Modified influenza vaccine candidates have been developed in collaboration with GSK
Read Moreby John Pinching | Apr 19, 2023 | News | 0
Link-up has already delivered data showing the promise of nanoparticle-formulated doggybone DNA
Read Moreby John Pinching | Apr 17, 2023 | News | 0
Group B streptococcus vaccine study will involve adult groups with and without underlying conditions
Read Moreby John Pinching | Apr 13, 2023 | News | 0
Notable first clearance for R21/Matrix-M malaria vaccine for use in a specific country
Read Moreby John Pinching | Apr 11, 2023 | News | 0
Company’s candidate, in combination with MSD’s Keytruda, receives PRIME designation
Read Moreby John Pinching | Mar 2, 2023 | News | 0
European Medicines Agency has issued a positive opinion for the use of VLA2001 among certain adults
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479